Opening soonPhase 2Ages 18 Years and up
Hyperthermia Enhanced Re-irradiation of Loco-regional Recurrent Tumors
Sponsor: Charite University, Berlin, Germany · NCT04889742 on ClinicalTrials.gov ↗
Conditions studied
Recurrent CancerProstate CancerCervical CancerAnal CancerSarcomaRectal CancerNeuroendocrine TumorsEsophageal CancerPancreas CancerSquamous Cell Carcinoma
What it tests
- loco-regional hyperthermiadevice
Where it's running1 site
1 international site
Klinik für Radioonkologie und Strahlentherapie
Berlin, Germany 13353
- Sebastian Zschaeck, M.D.(contact)
See the official eligibility language
Shown exactly as written on ClinicalTrials.gov. Your oncologist is the right person to judge whether it fits your situation.
Inclusion Criteria: * prior radiotherapy of the treatment side with a treatment dose \> 30 Gray (Gy) EQD2 (calculated with alpha/beta value of 9) * local/ regional / or oligometastatic tumor recurrence. Maximum number of three macroscopic tumor lesions with at least one of them receiving prior radiotherapy * macroscopic tumor recurrence * side of recurrence is amenable to hyperthermia (abdomen, pelvis, extremities, spine, cervical lymphnodes) * planned re-irradiation dose of at least 40 Gy EQD2 (calculated with alpha/beta value of 9) Exclusion Criteria: * \>3 macroscopic tumor lesion * brain metastases * recurrence is amenable to local ablative radiotherapy (brachytherapy or stereotactic radiotherapy) * recurrence region is not amenable to hyperthermia (lung, liver, mediastinum) * contraindications for hyperthermia (serious cariovascular disease, ICD or larger implants at the treatment site) * psychiatric disorders that impede proper informed consent * serious comorbidities with very limited prognosis quo ad vitam
Updated 2023-12-26 on ClinicalTrials.gov. Always confirm current details with the study team or your oncologist.